Alamar Biosciences Q3 2026 net loss widens 66% year over year to $13.3 million; Q3 2026 revenue rises 68% year over year to $33.5 million

Bitget2026/11/03 22:37

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Alamar Biosciences’ Q3 2026 net loss widened 66% year over year to $13.3 million.
Revenue climbed 68% year over year to $33.5 million, while consumable revenue rose 79% to $17.8 million.
Total operating expense jumped 81% year over year to $35.8 million.
The NULISA platform was selected to profile 80,000 samples for a UK Biobank neurodegeneration study.
FY26 revenue guidance increased to $121 million–$123 million from $116 million–$120 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alamar Biosciences Inc. published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Alamar Biosciences Q3 2026 net loss widens 66% year over year to $13.3 million; Q3 2026 revenue rises 68% year over year to $33.5 million

You may also like

Crypto prices